ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy
Betsy Goodfellow | July 23, 2024 | News story | Research and Development | GSK, HIV, HIV/AIDS, ViiV Healthcare, maintenance therapy
GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with Pfizer and Shionogi as shareholders, has shared 48-week data from its PASO DOBLE (GeSIDA 11720 study).
The trial evaluated the company’s two-drug regimen Dovato (dolutegravir/lamivudine) compared to the three-drug regimen Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide fumarate) for the treatment of HIV-1 in patients who are virologically supressed and could benefit from treatment optimisation.
The results showed that switching to the two-drug programme in virologically suppressed adults with HIV demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to the three-drug programme.
Full results are expected to be presented at the 25th International AIDS Conference (AIDS 2024) being held from 22-26 July 2024 in Munich, Germany.
Harmony P Garges MD MPH, chief medical officer at ViiV Healthcare, commented: “The results from PASO DOBLE show that Dovato demonstrated non-inferior efficacy compared to Biktarvy, and that the average weight gain for trial participants taking DTG/3TC was significantly lower than those taking BIC/FTC/FTC over the course of the year. This is a meaningful outcome, as treatment-related weight gain is an important topic for many people living with HIV. At ViiV Healthcare we’re dedicated to bringing innovative HIV treatments to people living with HIV that are not only safe and effective, but also address their specific needs beyond viral suppression.”
Betsy Goodfellow
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
European Commission approves HIV prevention injection
The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
